<DOC>
	<DOCNO>NCT01705652</DOCNO>
	<brief_summary>The purpose study ( 1 ) determine rate PSA decline ( number decline ) . Tissue obtain ancillary study ( 2 ) determine number patient PSA decline &lt; 1.0 ng/ml 3 month patient receive Nexrutine® standard radiation therapy . The Secondary Objective confirm tolerability regimen . The Third Objective ( Ancillary study ) To evaluate molecular response Nexrutine® . Molecular response define change molecular pathway .</brief_summary>
	<brief_title>Study Assess Activity Nexrutine® Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Have histologic diagnosis prostate cancer ( 1 core ) one following : Gleason &gt; 6 , Unilateral Gleason 6 ≥ 3 core , bilateral Gleason 6 , PSA &gt; 10.0 ng/ml . 2 . Age ≥18 year . 3 . Has ECOG Performance Status 02 Karnofsky 60100 . 4 . Has follow laboratory value study entry : absolute neutrophil count ( ANC ) ≥ 1,500 cells/μL ; platelet count ≥ 100,000 cells/μL ; hemoglobin ≥ 9 g/dL ; total serum bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) ; ALT AST ≤ 1.5 x institutional ULN alkaline phosphatase ≤ULN creatinine BUN ≤ 1.5 x institutional upper limit normal ( ULN ) 5 . Signed informed consent 6 . No new , undiagnosed bone pain negative bone scan . ( within 2 month consent ) If bone pain , bone scan require . 1 . Has document metastatic disease . 2 . Has receive prior chemotherapy androgen ablation . 3 . Has receive prior immunotherapy . 4 . Has previously treat Strontium , Samarium , systemic radioisotope radiation therapy . 5 . Has diagnosis congestive heart failure 6 . Currently take anticoagulation medication , i.e. , coumadin heparin . Over counter aspirin ibuprofen allow . 7 . Is receive investigational agent cancer . 8 . Has history malignancy within last 5 year , could affect diagnosis assessment prostate cancer . 9 . Has serious intercurrent illness life expectancy le 5 year . 10 . Has concomitant medical , psychological , social circumstance , would interfere compliance protocol treatment followup . 11 . Use herbal alternative regimen , may antineoplastic hormonal activity ( include limit finasteride , dutasteride , Saw Palmetto , PCSPES , shark cartilage , etc ) , prohibit receive study treatment . 12 . Clinical stage T3 T4 PSA &gt; 10 ng/ml Gleason &gt; 8 . 13 . Patient receive adjuvant androgen ablation radiation . 14 . EKG show baseline QTc &gt; 450 msec ischemic change . For ischemic change , patient eligible evaluate clear internal medicine . 15 . Previous history druginduced QTc prolongation and/or concurrent treatment medication know produce suspect QT prolongation .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>nexrutine</keyword>
	<keyword>prostate cancer</keyword>
</DOC>